These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 28758583)

  • 21. Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity.
    Tuplin EW; Holahan MR
    Curr Neuropharmacol; 2017 Nov; 15(8):1192-1207. PubMed ID: 28412910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine D2 receptors as treatment targets in schizophrenia.
    Seeman P
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetic approaches to cognitive enhancement in schizophrenia.
    Burdick KE; Gopin CB; Malhotra AK
    Harv Rev Psychiatry; 2011; 19(3):102-8. PubMed ID: 21631157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonergic mechanisms as targets for existing and novel antipsychotics.
    Meltzer HY
    Handb Exp Pharmacol; 2012; (212):87-124. PubMed ID: 23129329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical antipsychotic agents: a critical review.
    Worrel JA; Marken PA; Beckman SE; Ruehter VL
    Am J Health Syst Pharm; 2000 Feb; 57(3):238-55. PubMed ID: 10674777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.
    Gacsályi I; Nagy K; Pallagi K; Lévay G; Hársing LG; Móricz K; Kertész S; Varga P; Haller J; Gigler G; Szénási G; Barkóczy J; Bíró J; Spedding M; Antoni FA
    Neuropharmacology; 2013 Jan; 64():254-63. PubMed ID: 22824189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP
    J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update.
    Scharfetter J
    Pharmacogenomics; 2004 Sep; 5(6):691-8. PubMed ID: 15335289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can genetics inform the management of cognitive deficits in schizophrenia?
    Vyas NS; Shamsi SA; Malhotra AK; Aitchison KJ; Kumari V
    J Psychopharmacol; 2012 Mar; 26(3):334-48. PubMed ID: 22328662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histamine H
    Mahmood D
    Int J Health Sci (Qassim); 2016 Oct; 10(4):564-575. PubMed ID: 27833522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
    Meltzer HY; Elkis H; Vanover K; Weiner DM; van Kammen DP; Peters P; Hacksell U
    Schizophr Res; 2012 Nov; 141(2-3):144-52. PubMed ID: 22954754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.
    Burstein ES; Ma J; Wong S; Gao Y; Pham E; Knapp AE; Nash NR; Olsson R; Davis RE; Hacksell U; Weiner DM; Brann MR
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1278-87. PubMed ID: 16135699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia.
    Watson DJG; King MV; Gyertyán I; Kiss B; Adham N; Fone KCF
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):208-224. PubMed ID: 26723167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine partial agonists: a new class of antipsychotic.
    Lieberman JA
    CNS Drugs; 2004; 18(4):251-67. PubMed ID: 15015905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia.
    de Bartolomeis A; Ciccarelli M; Vellucci L; Fornaro M; Iasevoli F; Barone A
    Expert Opin Pharmacother; 2022 Dec; 23(18):2035-2052. PubMed ID: 36368055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.
    Lane HY; Lee CC; Liu YC; Chang WH
    Pharmacogenomics; 2005 Mar; 6(2):139-49. PubMed ID: 15882132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of serotonin in the action of atypical antipsychotic drugs.
    Meltzer HY
    Clin Neurosci; 1995; 3(2):64-75. PubMed ID: 7583621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders.
    De Deurwaerdère P
    Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.